RxDoctor Payments Data

Steven Rhee, DO

Ophthalmology · Wahiawa, HINPI 1104884717

Payments from drug & device makers

$1,729in general payments, 2019–2025

Across 51 payments — averaging $33.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$743
  • Johnson & Johnson Surgical Vision, Inc.$366
  • Sight Sciences, Inc.$148
  • Regeneron Healthcare Solutions, Inc.$122
  • Dompe US, Inc.$114
  • Hoffmann-la Roche Limited$81
  • plus $155 from 4 others

What the payments were for

  • Food & beverage$1,729100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,729 in reported general payments places this provider in the 40th percentile of 120 ophthalmology providers in Hawaii.

See all ophthalmology providers in Hawaii

Medicare billing

Part B allowed, 2024
$258,234
Medicare patients
635
Services billed
2,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost166$91,550
Prednisolone Acetate557$32,985
RestasisCyclosporine28$27,358
RhopressaNetarsudil Mesylate46$26,133
LumiganBimatoprost29$18,248
Latanoprost606$11,565
Diclofenac Sodium502$5,537
Brimonidine Tartrate228$4,956
Timolol Maleate168$4,447
Alphagan PBrimonidine Tartrate11$4,402
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat291$3,734
Brinzolamide16$3,166
Dorzolamide Hcl38$780
Ketorolac Tromethamine26$644
Ofloxacin35$569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$71$117,683212 claims
AbbVieRestasis, Lumigan, Alphagan P$43$50,00768 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 120 ophthalmology providers in Hawaii.

Other ophthalmology in Wahiawa

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →